GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Inc (NAS:IXHL) » Definitions » Valuation Rank

IXHL (Incannex Healthcare) Valuation Rank


View and export this data going back to 2022. Start your Free Trial

What is Incannex Healthcare Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Incannex Healthcare Valuation Rank Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Incannex Healthcare Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Inc (NAS:IXHL) » Definitions » Valuation Rank
Comparable Companies
RAPH RSCI CYTH DRRX INIS FLGC TXMD TLPH GELS BIOE ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Website
https://www.incannex.com.au
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.